GlassScriptPhysician profile
Karen Lee Menser
NPI 1851698294
$1,180.39
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $470 · 2023: $340 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.84 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $157.03 | 2022-2023 | Veozah |
| Abbvie INC. | $153.36 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $139.27 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $117.18 | 2021 | |
| Boston Scientific Corporation | $117.15 | 2022 | |
| Alexion Pharmaceuticals, INC. | $113.40 | 2024 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $113.05 | 2022 | |
| Neurelis, INC. | $91.82 | 2023 | Valtoco |
| Novo Nordisk INC | $50.15 | 2023 | Wegovy |
| Mayne Pharma Commercial LLC | $48.47 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.84 | 2022 | |
| Exeltis, USA INC. | $15.81 | 2023 | Slynd |
| Biohaven Pharmaceutical Holding Company LTD. | $13.72 | 2022 | |
| Organon LLC | $12.14 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Menser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.